Tech

Amazon Debuts GLP-1 Weight-Loss Program via One Medical

Amazon is rolling out a GLP-1 weight-loss program through its One Medical unit, embedding obesity care inside Amazon Pharmacy. The service offers Wegovy and Zepbound access and adds newer oral GLP-1 options, signaling a bold expansion of Amazon's healthcare ambitions.

📅 April 21, 2026
⏱️ 2 min read
Amazon Debuts GLP-1 Weight-Loss Program via One Medical

Key Takeaways

  • The program includes Wegovy and Zepbound and flags newer oral GLP-1 options within the Amazon ecosystem.
  • Insured pricing starts at $25 per month; cash-paying oral drugs from $149 per month; injectables from $299 per month.
  • On-demand renewals cost $29 for a message consult and $49 for video care.
  • Amazon aims to expand same-day drug delivery to 4,500 cities by the end of 2026.
  • Obesity-drug stocks fell after the announcement, underscoring near-term investor concerns about payers and competition.

People Involved

  • No specific individuals mentioned

Entities Involved

  • Amazon.com, Inc. (AMZN) E-commerce and healthcare platform launching GLP-1 program through One Medical
  • Novo Nordisk A/S (NVO) Maker of Wegovy and a leading GLP-1 drug provider
  • Eli Lilly and Company (LLY) Maker of Zepbound and a major GLP-1 player
  • Hims & Hers Health, Inc. (HIMS) Public obesity-drug-related stock affected by the announcement
  • Viking Therapeutics, Inc. (VKTX) Biotech stock visibly moved in response to GLP-1 news
  • Amgen, Inc. (AMGN) Peer GLP-1/obesity-drug exposure within the sector
  • Septerna, Inc. (SEPN) Biotech involved in GLP-1 pathway research and related space

MarketMoodz Analysis

Investors should see upside in higher Amazon Pharmacy volumes, deeper cross-sell with Prime, and stronger chronic-care engagement as patients stay within the ecosystem. Scaling logistics and pricing could widen margins by routing more pharmacy revenue through Amazon’s fulfillment network and locking patients into ongoing GLP-1 care.

Historically, Novo Nordisk and Lilly have dominated GLP-1 obesity drugs; this move introduces a major online distribution channel and a new care model that could pressure traditional retailers and payers to negotiate more favorable terms if uptake accelerates. Watch for payer coverage decisions, regulatory scrutiny over GLP-1 marketing, and updates on One Medical materials and regional rollout plans.

Source: Original Article

Get AI-Powered Market Insights

Stay ahead of market-moving events with our real-time analysis and stock ratings.

Start Your Free Trial